Form 4: Vera Therapeutics Director Acquires Stock Options

Vera Therapeutics Director Scott W. Morrison was granted stock options for 17,084 shares of Class A Common Stock.

Summary

• Scott W. Morrison, a Director at Vera Therapeutics, Inc., was granted stock options on May 21, 2026.
• The options are for 17,084 shares of Class A Common Stock.
• The exercise price for these options is $34.35 per share.
• These options have an expiration date of May 20, 2036.
• The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, provided continuous service is maintained.
• Vesting will also occur in full upon a change in control, subject to continuous service through that event.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a director rather than a significant financial or strategic update for the company.

Positives

• Director granted significant stock options, indicating potential alignment of management interests with shareholder value.
• Vesting schedule tied to service and potential change in control provides incentives for long-term commitment and value creation.
• The exercise price of $34.35 suggests a valuation expectation for the company's stock.

Negatives

• The filing only details the grant of options and does not provide information on the company's current financial performance or operational status.

Risks

• The value of the stock options is contingent on the future performance of Vera Therapeutics' stock price, which is subject to market volatility and company-specific risks.
• Failure to meet continuous service requirements could result in forfeiture of the vested options.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance and the fulfillment of service conditions by the reporting person. The vesting schedule indicates potential future value realization for the director.

Management Comments

• The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
• Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.

Industry Context

StockSavvy.ai notes that the grant of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with long-term company growth and potential exit events like acquisitions.

Stakeholder Impact

• Shareholders: The grant of options aligns director incentives with potential future stock price appreciation, which can be positive if the company performs well.
• Employees: May indirectly benefit from strong leadership and aligned incentives, potentially leading to better company performance.
• Management: The reporting person benefits from the potential to acquire company stock at a predetermined price.

Next Steps

• Continuous service by Scott W. Morrison through the vesting dates.
• Potential vesting upon a change in control event.
• Monitoring of Vera Therapeutics' stock performance to determine the value of the granted options.

Key Dates

Keywords

Vera Therapeutics, VERA, Form 4, Stock Options, Director, Beneficial Ownership, Securities, SEC Filing, Grant Date, Vesting Schedule